Phosphodiesterase type 5 inhibitors enhance chemotherapy in preclinical models of esophageal adenocarcinoma by targeting cancer-associated fibroblasts.
Sharpe BP, Hayden A, Manousopoulou A, Cowie A, Walker RC, Harrington J, Izadi F, Breininger SP, Gibson J, Pickering O, Jaynes E, Kyle E, Saunders JH, Parsons SL, Ritchie AA, Clarke PA, Collier P, Mongan NP, Bates DO, Yacqub-Usman K, Garbis SD, Walters Z, Rose-Zerilli M, Grabowska AM, Underwood TJ.
Sharpe BP, et al. Among authors: ritchie aa.
Cell Rep Med. 2022 Jun 21;3(6):100541. doi: 10.1016/j.xcrm.2022.100541.
Cell Rep Med. 2022.
PMID: 35732148
Free PMC article.